Logo Image
News
Media
All VideosMedical World NewsPodcastsWeekly RecapCure ConnectionsInsightsSpecial ReportNeurologyLive Peer ExchangeMedcastPeers & PerspectivesRoundtable DiscussionsShortsShows & Podcasts
Conferences
Conference CoverageConference Listing
CME/CE
More
Partners
Publications
NeurologyLiveBridging the GapsInternational Journal of MS Care
Resources
Expert AuthorsFDA NewsFeaturesFuture Leaders in NeurologyGiants of Multiple SclerosisInteractive ToolsJob BoardLive EventsNeurology ResourcesParkinsonism Practical GuideSponsoredThe G.L.O.B.Virtual Events

Subscribe

  • News
  • Media
  • Conferences
  • CME/CE
  • Partners
  • Publications
  • Resources
  • Subscribe
  • Dementia and Alzheimer Disease
  • Epilepsy
  • Genetic Disorders
  • Headache and Migraine
    • Migraine
  • MS and Demyelinating Disorders
    • NMOSD
    • Multiple Sclerosis
  • Movement Disorders
    • Parkinson Disease
    • Dyskinesia
    • Huntington Disease
  • Neuro-Oncology
  • Neuromuscular
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Muscular Dystrophy
    • Ataxia
  • Rare Diseases
  • Sleep Disorders
    • Narcolepsy
    • Excessive Daytime Sleepiness
    • Insomnia
  • Stroke
Spotlight -
Expert Authors|
FDA News|
Upcoming Live Events|
CMSC 2026|
ATMRD 2026|
AAIC 2026|
Parkinsonism Practical Guide
Advertisement

Ben Wolff

Advertisement

Articles by Ben Wolff

James M. Chamberlain, MD

Diazepam as Effective as Lorazepam for Pediatric Status Epilepticus

ByBen Wolff
July 8th 2014
Advertisement

Latest Updated Articles

  • James M. Chamberlain, MD
    Diazepam as Effective as Lorazepam for Pediatric Status Epilepticus

    July 8th 2014



Advertisement
Advertisement

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

1

Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease

2

AD109 Accepted NDA, AXS-12 FDA Submission, Phase 2 CELIA Study Results

3

POLARIS-AD Phase 3 Trial of PDE5 Inhibitor AR1001 Completes Treatment Phase With Favorable Safety Profile

4

Mitophagy Activator Urolithin A Enters Phase 2 Alzheimer Trial of APOE4 Carriers

5

Anti-Tau Agent Diranersen Slows Cognitive Decline Across Multiple Endpoints in Phase 2 CELIA Trial, Biogen to Advance to Phase 3

  • About Us
  • Advisory Board
  • Editorial
  • Contact Us
  • Advertise
  • Contact MJH LS
  • Do Not Sell My Information
  • Terms and Conditions
  • Privacy
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

  • Contagion Live
  • CGT Live
  • Neurology Live
  • HCP Live
  • Oncology Live
  • Contemporary Pediatrics
  • Contemporary OBGYN
  • Urology Times
  • The Educated Patient
  • Patient Care Online
HCP Live Network
Brand Logo

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us